#USA #Burlington #Cancer Treatment #PAQ Therapeutics #KRAS Degraders

PAQ Therapeutics Strengthens Leadership for Cancer Drug Development

In an ambitious stride towards expanding its capabilities in addressing deadly cancers, PAQ Therapeutics recently appointed Dr. Andrew Krivoshik as its Chief Medical Officer (CMO). This move is pivotal for a year where the company is making strides in its clinical trials, particularly with its lead candidate, PT0253, which targets KRAS G12D mutations.

Dr. Krivoshik's impressive career is underscored by a wealth of experience spanning multiple therapeutic areas, which will be instrumental for PAQ as it propels forward. Among his achievements, he has played key roles in the development of several successful oncology therapies, such as XTANDI®, PADCEV®, and VYLOY®. This rich background confirms his capability to manage multifaceted oncology projects and contribute to the delivery of much-needed therapies to patients battling KRAS-driven cancers.

“We are thrilled to welcome Dr. Krivoshik on board,” said Nan Ji, co-founder and CEO of PAQ Therapeutics. “His extensive background in oncology development aligns perfectly with our mission to bring innovative treatments to market.” This sentiment reflects the company’s determination to fill the void within oncology segments that lack effective treatment options, particularly malignant tumors that carry specific KRAS mutations.

In addition to Dr. Krivoshik's appointment, PAQ Therapeutics announced the addition of notable advisors to its clinical advisory board, including Dr. Eric H. Rubin and Dr. Piro Lito. Dr. Rubin comes with over three decades of experience in cancer drug development and was pivotal in the emergence of pembrolizumab, the first anti-PD-1 therapy approved in the U.S. His expertise will undoubtedly guide PAQ as it navigates through the complexities of clinical trials with its unique pipeline.

Meanwhile, Dr. Piro Lito, a distinguished member of the Memorial Sloan Kettering Cancer Center, brings his expertise in RAS mutations and targeted therapies to the table. As various RAS-directed therapies have shown promising outcomes, Dr. Lito's involvement positions PAQ Therapeutics to make substantial advancements in oncology treatment options. “I am thrilled to collaborate with the PAQ team at such a critical time in their research and development,” he expressed. “Targeting KRAS mutations through innovative approaches truly holds immense potential for improving outcomes in patients.”

PAQ Therapeutics aims to not only push its lead product into clinical use but also advance additional pipeline candidates under the expert oversight of its new leadership team. The focus remains firmly set on developing effective solutions for cancer treatments that address a significant unmet need.

As the company's developments proceed in the arena of biopharmaceuticals, the leadership team is optimistic about the promising future before them. “Our goal is to translate groundbreaking research into effective treatments for patients suffering from lethal cancers characterized by KRAS mutations,” concluded Dr. Krivoshik. “I'm excited to begin this journey with PAQ as we strive to make a meaningful impact in the lives of those affected by these devastating diseases.”

With these strategic enhancements in its leadership and advisory board, PAQ Therapeutics is well-positioned to make strides in developing innovative cancer therapies aimed at addressing the challenges associated with KRAS mutations, paving the way for future collaborations and groundbreaking discoveries in biotechnology.